3D Systems Corporation (DDD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. The company's cost reduction and R&D investments are positive, but the withdrawal of 2025 guidance and uncertainty in capital spending are concerning. The dental market expansion, especially with the NextDent 300, shows promise, yet the aligner business decline and vague profitability timelines weigh negatively. The Q&A reveals cautious optimism, but management's unclear responses on some issues add uncertainty. Overall, the sentiment is neutral with no strong catalysts for a significant stock price move.
Key Financial Performance
Revenue Second quarter consolidated revenue was $95 million, down 16% year-over-year or 11% when excluding Geomagic. Sequentially, revenue was up modestly and when adjusting for Geomagic in Q1, we saw 8% growth. The decline was primarily driven by printer and material softness in consumer-facing end markets, while Aerospace and Defense nearly doubled revenues from last year and grew over 50% from the prior quarter.
Industrial Solutions Revenue $50 million, declined 23% or 13% excluding Geomagic. This was primarily driven by printer and material softness in consumer-facing end markets. Aerospace and Defense partially offset this decline by nearly doubling revenues from last year and growing over 50% from the prior quarter.
Healthcare Solutions Revenue $45 million, decreased 8% from the previous year, predominantly driven by Dental with 2024 representing a significant year of purchases by a specific customer. MedTech delivered impressive growth, up 13% from last year and 16% from last quarter.
Non-GAAP Margin 39%, compared to 41% in the prior year and 38% when adjusted to exclude Geomagic. Performance for the second quarter was very strong and also delivered a significant improvement on a sequential basis, primarily attributable to favorable manufacturing variances given higher volume and cost efficiencies.
Non-GAAP Operating Expense $47 million, down 27% year-over-year and 24% sequentially. This improvement reflects the impact of restructuring actions, which drove meaningful efficiencies across nearly every function and geography, along with significantly reduced spend on external services.
Adjusted EBITDA Negative $5 million, significantly improved from the prior year by $8 million and prior quarter by $19 million, a testament to profitability first execution.
GAAP Net Income $104 million for the quarter, resulting in GAAP earnings per share of $0.57, up $0.78 per share from prior year. This was due to gains related to the Geomagic asset sale and proactive debt repayment at a discount.
Non-GAAP Loss Per Share $0.07, an improvement compared to $0.14 per share loss in the prior year.
Cash and Cash Equivalents Over $116 million in cash and cash equivalents and $17 million in restricted cash, totaling $134 million. This compared to $171 million at the end of last year, with the decline driven by $60 million used in operations, $113 million generated by investing activities, and $97 million used in financing activities.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New FDA-cleared NextDent Jetted Denture Solution: This product redefines dental prosthetics with single-piece multi-material dentures, offering improved aesthetics, comfort, and resistance to breakage. It enhances efficiency by up to 300% compared to traditional methods and targets a U.S. market expected to reach $600 million by 2029.
MedTech Business Expansion: The MedTech business grew 13% year-over-year and 16% sequentially, reaching over $80 million in annual revenue. It focuses on personalized solutions for craniomaxillofacial implants and trauma applications, with an addressable market of over $40 billion in 2024.
Aerospace and Defense Growth: Revenues nearly doubled year-over-year and grew over 50% sequentially, contributing over $30 million annually. Growth was driven by the 3P strategy (process, parts, printers) and wins in U.S. Naval and Air Force projects.
Cost Reduction Initiatives: The company targets $85 million in annualized savings by mid-2026 through restructuring, in-sourcing manufacturing, and reducing OpEx. Q2 OpEx was reduced by 27% year-over-year and 24% sequentially.
Manufacturing and Supply Chain Optimization: Efforts include reducing global footprint by over 50% by mid-2026, Lean and Six Sigma implementations, and improved inventory control. These actions aim to enhance gross margins and operational efficiency.
Restructuring and Profitability Focus: The company is aligning costs with market conditions to achieve positive cash flow by 2026. This includes streamlining R&D investments and focusing on core markets with high ROI.
Regenerative Medicine Program: The program achieved a significant milestone in 3D-printed human lung development, marking progress in partnership with United Therapeutics. However, investment in Systemic Bio was curtailed due to long commercialization timelines.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Year-over-year revenue declined by 16%, primarily due to a rapid drop in customers' CapEx spending for new production capacity, driven by uncertainty around tariffs.
Tariff Uncertainty: Uncertainty around tariffs has caused large OEM customers to delay capital investments, impacting revenue and creating volatility in financial performance.
Restructuring Challenges: Aggressive cost restructuring is underway to align with market conditions, but timing and execution risks remain, particularly in achieving gross margin improvements.
R&D Investment Cuts: Reduction in R&D spending and shelving of long-term projects like Systemic Bio could impact future innovation and competitiveness.
Supply Chain and Tariff Impact: Global supply chains remain complex and are further impacted by rapid tariff changes, increasing component costs and operational challenges.
Healthcare Business Dependency: The healthcare business, particularly MedTech, is a key growth area but remains dependent on expanding FDA-cleared products and scaling operations, which could face regulatory and operational hurdles.
Debt and Cash Flow Management: The company has significant debt obligations and is targeting positive cash flow by 2026, but this is contingent on successful cost reductions and market stabilization.
Market Volatility: Revenue volatility is expected to continue quarter-to-quarter until the tariff situation stabilizes, creating uncertainty in financial planning.
Operational Streamlining Risks: Efforts to consolidate global operations and reduce facilities by over 50% by mid-2026 carry risks related to execution and potential disruptions.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects meaningful revenue growth in the years ahead, particularly in MedTech and Aerospace and Defense markets, which are growing rapidly.
Profitability: The company aims to achieve positive cash flow by 2026 through restructuring and cost reduction initiatives, targeting over $85 million in annualized savings by mid-2026.
Operational Efficiency: Plans to reduce operational expenses (OpEx) to the low $40 million range by Q4 2025 and achieve over $85 million in annualized savings by mid-2026 through cost reductions and efficiency improvements.
Healthcare Business Expansion: The MedTech business is expected to grow significantly, with a focus on expanding orthopedic-related products and services, including FDA-cleared surgical guides and medical implants. The company is also expanding point-of-care services in hospitals.
Dental Market: The company has launched the NextDent Jetted Denture Solution for the U.S. market, targeting a $600 million addressable market by 2029.
Manufacturing and Supply Chain: Plans to consolidate global production and service capabilities, reducing the footprint by over 50% through mid-2026, to improve efficiency and reduce costs.
Aerospace and Defense: The Aerospace business is expected to continue its strong growth trajectory, with revenues nearly doubling year-over-year in Q2 2025.
Regenerative Medicine: The company continues to develop 3D-printed human lungs in partnership with United Therapeutics, with significant progress in technical milestones.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: In late June, the company repurchased $8 million of its common shares to reduce dilution. This was part of a broader financial strategy that also included retiring $88 million in outstanding debt at a discount and extending the maturity of the majority of its debt to 2030.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you break down the $80 million for MedTech between hardware and customized healthcare services?
A:The vast majority of the $80 million is from personalized health services. Printer sales into the market are relatively modest, influenced by the tariff situation. Most revenue comes from services and parts.
Q:Is healthcare combined as MedTech, Dental, and Lungs?
A:Yes, healthcare includes MedTech, Dental, and Lungs. MedTech now encompasses more under the orthopedic banner, and Regenerative is a new area.
Q:What is the update on Dental progress, particularly with the NextDent 300?
A:The U.S. dental market is approximately $400 million, with a similar size in Europe. 3D printing of dentures offers favorable economics and faster production. FDA certification has been achieved, and production is ramping up in Q3 and Q4. Next year, it is expected to be a material contributor to the Dental business.
Q:Can you confirm gross margins ex-revenue milestone and provide thoughts on margins for the next quarters?
A:Gross margins ex-revenue milestone are about 38%. The milestone revenue caused a spike in Q2 margins. For the rest of the year, margins are expected to normalize to levels seen earlier in the year, with continued focus on manufacturing efficiencies.
Q:Was the dental business, excluding the aligner business decline, down about 3%?
A:Including the 19% drop in aligners, the total Dental business was down 3%. The aligner business decline was anticipated and attributed to economic factors.
Q:Is the broader dental business improving without the contribution of NextDent 300?
A:Yes, the broader dental business is improving without NextDent 300. The dental industry is favorable for 3D printing, and the company is expanding into areas like nightguards, Vertex and NextDent materials, and dentures. Regulatory approvals in Europe and other regions are expected in the next 12-18 months.
Q:Is providing trained staff for point-of-care service a significant revenue generator?
A:No, it is not a significant revenue generator. It is a paid service that helps develop applications and move into new markets, such as trauma and cancer treatment for bones. It is more of an application development tool than a revenue stream.
Q:What is the update on the broader macro environment and its impact on sales cycles and activity?
A:Before April, CapEx spending was sluggish due to interest rate concerns. After April, the volatile tariff environment caused delays in CapEx decisions. However, there is increasing demand for short-term parts supply, especially in the metal arena. The situation is stable but uncertain due to tariffs.
Q:Will the dental opportunity be mostly a CapEx sale or involve services?
A:The dental opportunity will follow the traditional model of selling printers, consumables, and services. The printers are relatively inexpensive, making them accessible to regional labs and even dentist offices. The return on investment is favorable, with a payback period of about one year.
Q:What is the progress on the cost reduction program and EBITDA profitability targets?
A:The cost reduction program is on track, with headcount changes largely completed. Facility exits and subleases are ongoing and may take time. The company is confident in reaching EBITDA profitability at mid-90s revenue levels, but exact timing depends on sublease agreements.
Q:What are the exciting markets for the second half, such as aerospace, defense, and AI infrastructure?
A:Aerospace and defense are growing markets, with $30 million in trailing 12-month revenue. AI infrastructure is focused on thermal management for data centers and semiconductor manufacturing. Oil and gas is another area of demand, particularly for inventory management and on-demand 3D printing.
Q:Will R&D spending come down in the following quarters or next year?
A:Yes, R&D spending will decrease to mid-teens as a percentage of sales. The company has completed a major refresh of its product line and will now focus on maintaining and refreshing products periodically. Some long-term projects, like Systemic Bio, have been curtailed to focus on areas with clear ROI.
Q:What is the progress on in-sourcing manufacturing and supply chain operations?
A:In-sourcing is virtually complete, improving product quality and efficiency. It benefits COGS and gross margin by reducing reliance on contract manufacturing and enabling cost control. Efforts are ongoing to qualify onshore suppliers to mitigate tariff impacts.
Q:Are customers discussing buying systems to mitigate tariffs?
A:Yes, customers are discussing buying systems to mitigate tariffs, but the challenge is deciding where to place the equipment due to the volatile tariff environment. The company is bridging this gap by offering limited parts production until customers make CapEx decisions.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the expected penetration rate of the NextDent 300 market, stating only that the economics are favorable and feedback has been great. Additionally, they were vague about the exact timing for achieving EBITDA profitability, citing factors like sublease agreements and facility exits as variables.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Creech
LLC Research
MedTech
RD investment
Research Division
Slide
action
application
area
capability
chain
customer
decision
efficiency
effort
footprint
hospital
improvement
level
manufacturing
market
material
metal
milestone
model
part
patient
period
point
polymer
portfolio
potential
process
product
production
profitability
quantity
reduction
result
service
stage
success
tariff
testing
value
year
DDD Transcript
3D Systems Corporation (DDD) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call summary indicates strong financial performance with 11% YoY revenue growth and improved EBITDA, driven by robust growth in key sectors like Med Tech and Aerospace & Defense. Despite supply chain disruptions and economic risks, the company achieved positive EBITDA and improved margins. The Q&A section highlighted strategic expansions and product portfolio refreshes, indicating future growth potential. However, cautious guidance due to global volatility is noted. Overall, these factors suggest a positive sentiment, likely leading to a stock price increase in the 2% to 8% range.
3D Systems Corporation (DDD) Q4 2025 Earnings Call Transcript
Unknown3-9
The earnings call presents a mixed picture: while there's sequential revenue growth and positive developments in sectors like aerospace and defense, the overall year-over-year revenue declined by 9%. The company improved its EBITDA and reduced operating expenses, but gross margins were negatively impacted by a less favorable product mix. The Q&A revealed cautious guidance and some uncertainty, especially around consumer segments. Given these factors, the stock price is likely to remain stable with minor fluctuations, resulting in a neutral sentiment.
3D Systems Corporation (DDD) Q3 2025 Earnings Call Transcript
Unknown11-5
The earnings call reflects a negative sentiment due to a significant revenue decline, reduced gross margins, and a net loss. Despite some cost-cutting improvements and new partnerships, the lack of clear guidance on achieving breakeven and the unclear management responses in the Q&A section contribute to investor uncertainty. The positive developments in the dental market and new partnerships are overshadowed by the overall financial performance and market concerns, leading to a likely negative stock price reaction.
3D Systems Corporation (DDD) Q2 2025 Earnings Call Transcript
Unknown8-12
The earnings call presents a mixed picture. The company's cost reduction and R&D investments are positive, but the withdrawal of 2025 guidance and uncertainty in capital spending are concerning. The dental market expansion, especially with the NextDent 300, shows promise, yet the aligner business decline and vague profitability timelines weigh negatively. The Q&A reveals cautious optimism, but management's unclear responses on some issues add uncertainty. Overall, the sentiment is neutral with no strong catalysts for a significant stock price move.
DDD Slides
DDD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
